glp-1 obesity drug supply news today What is the pipeline for future medications for obesity?

Prenatal exposure to GLP-1 receptor agonists and other second-line antidiabetics may not pose greater risk to infants than insulin | Harvard T.H. Chan School of Public Health

GLP1 receptor agonists are supported by preclinical and observational evidence for reducing addictive behaviors, particularly alcohol and nicotine use. Initial randomized clinical trials indicate possible reductions in craving and substance intake, though

Comparing Ozempic, Wegovy and Other GLP-1 Drugs - GoodRx

Starting January 1, 2025, Kaiser Permanente will be making adjustments to the coverage of GLP-1 drugs and other Anti-Obesity Medications (AOMs) in California commercial plans. For members with a BMI less

GLP-1s are building a reputation as wonder drugs. But how, on the molecular level, do GPL-1 drugs work? How do they deliver benefits like fat loss or pancreatic health improvements? Salk Institute